Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR | P43119 | 12/20 | 0.54 |
| ▸ | PTGDR | Q13258 | 6/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | AXL | P30530 | 1/20 | 0.43 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.43 |
| ▸ | MERTK | Q12866 | 1/20 | 0.43 |
| ▸ | COMT | P21964 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.42 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.42 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.42 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3946944 | 0.96 | PTGIR (0.52) | PTGIRPTGDRL3MBTL1COMTGABRA1 | |
| SCHEMBL395224 | 0.94 | PTGIR (0.58) | PTGIRPTGDRL3MBTL1AXLTYRO3 | |
| SCHEMBL395000 | 0.90 | PTGIR (0.56) | PTGIRPTGDRL3MBTL1AXLTYRO3 | |
| SCHEMBL4179474 | 0.87 | PTGIR (0.52) | PTGIRPTGDRL3MBTL1AXLTYRO3 | |
| SCHEMBL3948983 | 0.83 | PTGIR (0.58) | PTGIRPTGDRL3MBTL1 | |
| SCHEMBL3943299 | 0.83 | PTGIR (0.54) | PTGIRPTGDRL3MBTL1AXLTYRO3 | |
| SCHEMBL395074 | 0.83 | SMN1; SMN2 (0.53) | COMTGABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL3939630 | 0.83 | SMN1; SMN2 (0.51) | PTGIRPTGDRCOMTGABRA1GABRG2 | |
| SCHEMBL394999 | 0.81 | SMN1; SMN2 (0.52) | PTGIRPTGDRL3MBTL1COMTGABRA1 | |
| SCHEMBL3937745 | 0.81 | PTGIR (0.51) | PTGIRPTGDRMERTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270399-A1 | NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS | KOWA CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| EP-1043317-B1 | PYRIDAZINE DERIVATIVES AND MEDICAMENTS CONTAINING THEM AS ACTIVE INGREDIENT | KOWA CO (JP) | 2009-04-15 | — | — | EP | disclosed |
| US-20090069332-A1 | NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS | KOWA CO., LTD. (JP) | 2009-03-12 | — | — | US | disclosed |
| EP-2017266-A1 | Pyridazine derivatives and medicines containing the same as effective ingredients | Kowa Co., Ltd. (JP) | 2009-01-21 | — | — | EP | disclosed |
| US-20080119474-A1 | NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS | KOWA CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| US-20070208025-A1 | NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS | KOWA CO., LTD. (JP) | 2007-09-06 | — | — | US | disclosed |
| US-20070049595-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | KOWA CO., LTD. (JP) | 2007-03-01 | — | — | US | disclosed |
| US-20060160804-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | KOWA CO., LTD. (JP) | 2006-07-20 | — | — | US | disclosed |
| US-20050267113-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | KOWA CO., LTD. (JP) | 2005-12-01 | — | — | US | disclosed |
| US-20050065155-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | KOWA CO., LTD. (JP) | 2005-03-24 | — | — | US | disclosed |
| US-20040147516-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | KOWA CO., LTD. (JP) | 2004-07-29 | — | — | US | disclosed |
| US-20020123496-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | KOWA CO., LTD. (JP) | 2002-09-05 | — | — | US | disclosed |
| US-6348468-B1 | THESE COMPOUNDS HAVE EXCELLENT INHIBITORY ACTIVITY AGAINST INTERLEUKIN-1.BETA. PRODUCTION, IMMUNE SYSTEM DISEASES, INFLAMMATORY DISEASES, ISCHEMIC DISEASES AND THE LIKE. | KOWA CO., LTD. (JP) | 2002-02-19 | — | — | US | disclosed |
| EP-1043317-A1 | NOVEL PYRIDAZINE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | Kowa Co., Ltd. (JP) | 2000-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208025-A1 | NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS | IL1B, IL1R1, TLR1 | PTGIR 248/4885PTGDR 801/4885L3MBTL1 1767/4885 |
| US-20050267113-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | IL1B, IL1R1, IRAK1 | PTGIR 277/4885PTGDR 944/4885L3MBTL1 1808/4885 |
| US-20090270399-A1 | NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS | IL1B, IL1R1, TLR1 | PTGIR 225/4885PTGDR 750/4885L3MBTL1 1892/4885 |
| US-20050065155-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | IL1B, TLR1, IRAK1 | PTGIR 257/4885PTGDR 762/4885L3MBTL1 1924/4885 |
| US-20040147516-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | IL1B, IRAK1, TLR1 | PTGIR 256/4885PTGDR 911/4885L3MBTL1 2306/4885 |
| US-20070049595-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | IL1B, TLR1, IRAK1 | PTGIR 257/4885PTGDR 762/4885L3MBTL1 1924/4885 |
| US-20060160804-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | IL1B, TLR1, IRAK1 | PTGIR 257/4885PTGDR 762/4885L3MBTL1 1924/4885 |
| US-20090069332-A1 | NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS | IL1B, IL1R1, TLR1 | PTGIR 225/4885PTGDR 750/4885L3MBTL1 1892/4885 |
| US-20020123496-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | IL1B, IRAK1, TLR1 | PTGIR 256/4885PTGDR 911/4885L3MBTL1 2306/4885 |
| US-20080119474-A1 | NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS | IL1B, IL1R1, TLR1 | PTGIR 248/4885PTGDR 801/4885L3MBTL1 1767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.